During the past decade, Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 8 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg" are "Breast Cancer" (5 trials), "Metastatic Breast Cancer" (3 trials), "Breast Neoplasms" (2 trials), "Triple-Negative Breast Cancer" (2 trials) and "Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg" in a lesser frequency.

Most popular intervention types in "Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg" are "Drug" (16 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Paclitaxel" (5 trials), "Pertuzumab" (5 trials), "Atezolizumab" (4 trials) and "Docetaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg" are 15 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".